International Circulation:  New clinical trials and registry studies have shown that the benefit of drug-eluting stents (DES) in terms of re-stenosis is not achieved at the expense of a compromised safety. What’s your opinion on the issue? Do you think the controversy over the safety of DES compared to bare metal stents (BMS) could be settled by current data?
《国际循环》：新的临床试验和注册研究结果已经显示，因为安全性的问题，药物洗脱支架（DES）没有取得对再狭窄的益处。请问您对这一问题的看法如何？您认为当前的研究数据能够解决DES相对于裸金属支架（BMS）的安全性争论吗？

Mark Turco:  I thing the data is very clear right now that this issue between DES safety versus BMS has been resolved.  The advocacy argument has been pretty clear that there is a marked reduction in target lesion revascularization rates with DES.  As you mentioned there has been this safety concern but I think the data out there now strongly supports the safety for DES and that is not the issue.  We still have the issue though of dual anti-platelet therapy and that is what we need to work on.  The key is to figure out who may be resistant to dual antiplatelet therapies， such as clopidagrel or aspirin resistance， and then try to remove the dependence on dual antiplatelet therapy.  Whenever we solve one question other questions come up. 
Mark Turco 教授：我认为现有的数据非常清楚地说明，DES相对于BMS的安全性问题已经得到解决。但是，从安全性的角度考虑，我们甚至需要比以前做得更好。对疗效的争论结果已经相当清楚，使用DES后靶病变血运重建率明显降低。像你所提到的，安全性问题一直存在，我认为，现有的数据强烈支持DES的安全性，这已经不是问题。现在我们仍然对一直使用的双重抗血小板治疗存在疑问。我们需要了解哪些患者可能对双重抗血小板治疗抵抗，如对氯吡格雷或阿司匹林抵抗，我们也需要努力消除对双重抗血小板治疗的依赖。使用较细支撑设计和新聚合物类型的新DES平台将有助于解决这一问题。